As of Aug 18
| +0.21 / +2.39%|
The 3 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 27.00, with a high estimate of 33.00 and a low estimate of 24.00. The median estimate represents a +200.67% increase from the last price of 8.98.
The current consensus among 3 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.